Jazz Pharmaceuticals holds the cleaner structural position, with the lead spread across valuation and growth. Elanco Animal Health still has the edge on valuation, which keeps the comparison from looking entirely one-sided. On the market side, Jazz Pharmaceuticals is in better shape — its trend is intact while Elanco Animal Health's trend has broken down. That puts structure and market broadly in agreement — Jazz Pharmaceuticals's lead looks more confirmed than conflicted.
The comparison is based on similar long-term financial trajectories, not sector labels. Both peer scores are relative to the Russell 1000 universe, making them directly comparable.
On valuation, the clearer edge sits with Elanco Animal Health Incorporated, while the overall score remains tighter and points the other way.
This comparison is anchored in long-term financial trajectory similarity within the selected peer universe.
This level of similarity signals a strong structural match, even though some dimensions still separate the two companies.
The clearest structural overlap shows up in investment intensity and margin consistency.
Scores reflect position relative to comparable companies with similar long-term financial trajectories.
The largest gaps do not all point in the same direction.
Left means cheaper relative valuation. Higher means stronger structure.
The price setup looks more supportive for Jazz Pharmaceuticals plc, but Elanco Animal Health Incorporated still has the stronger structure.
Valuation position uses Forward P/E and peer-relative PE percentile (idx_pct_pe) where available.
Where ELAN and JAZZ each sit in their own 5-year price and valuation history.
Describes historical entry positioning only. Descriptive — not investment advice.
The multiple-based pricing edge comes from a forward P/E that is 10.5 turns lower.
Elanco Animal Health Incorporated still shows lower market-fundamental divergence, which keeps the wider picture mixed rather than completely one-sided.
The lead is built on both valuation and growth — though valuation still provides a counterweight.
Break down the ELAN vs JAZZ comparison across all dimensions with the full interactive tool.
Explore how ELAN and JAZZ each compare against other companies in their peer groups.
Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.